Castor, Achilles and Hermes NC PTA Balloon Dilatation Catheter
K160941 · Brosmed Medical Co., Ltd. · LIT · Dec 13, 2016 · Cardiovascular
Device Facts
Record ID
K160941
Device Name
Castor, Achilles and Hermes NC PTA Balloon Dilatation Catheter
Applicant
Brosmed Medical Co., Ltd.
Product Code
LIT · Cardiovascular
Decision Date
Dec 13, 2016
Decision
SESE
Submission Type
Traditional
Regulation
21 CFR 870.1250
Device Class
Class 2
Attributes
Therapeutic
Indications for Use
The balloon dilatation catheter is intended to dilate stenoses in the iliac, femoral, iliofemoral, popliteal, infrapopliteal, and renal arteries, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for stent dilatation post-deployment in the peripheral vasculature.
Device Story
Castor, Achilles, and Hermes NC PTA Balloon Dilatation Catheters are over-the-wire (OTW) peripheral angioplasty devices. Input: manual inflation via side leg port; guide wire insertion via straight entry port. Operation: coaxial double-lumen catheter with non-compliant nylon balloon at distal tip; balloon expands to known diameter at specific pressures (12 atm nominal; 18-22 atm rated burst). Output: mechanical dilation of arterial stenoses or post-stent expansion. Used in clinical settings by physicians. Radiopaque markers aid in positioning relative to stenosis. Benefits: restores vessel patency; improves blood flow in peripheral vasculature and dialysis fistulae.
Clinical Evidence
Bench testing only. No clinical data. Performance testing included dimensional verification, balloon preparation/deployment/retraction, rated burst pressure, fatigue, compliance, inflation/deflation time, bond strength, tip pull strength, flexibility, kinking, torque, radiopacity, coating integrity, and particulate evaluation. Biocompatibility testing included cytotoxicity, sensitization, hemocompatibility, pyrogenicity, acute systemic toxicity, intracutaneous reactivity, and genotoxicity (bacterial mutagenicity and in vitro mouse lymphoma). All results met acceptance criteria.
Indicated for patients requiring dilation of stenotic lesions in iliac, femoral, iliofemoral, popliteal, infrapopliteal, and renal arteries, treatment of obstructive lesions in native or synthetic arteriovenous dialysis fistulae, and post-deployment stent dilatation in the peripheral vasculature.
Regulatory Classification
Identification
A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the United States Department of Health and Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol that resembles a stylized caduceus, a symbol often associated with medicine and healthcare.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
December 13, 2016
BrosMed Medical Co., Ltd. Ms. Tina Yin Regulatory Affairs Manager 15th Bldg., SMEs Venture Park Songshan Lake Hi-Tech Industrial Development Zone Dongguan 523808, China
Re: K160941
Trade/Device Name: Castor, Achilles, and Hermes NC PTA Balloon Dilatation Catheters Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter Regulatory Class: Class II Product Code: LIT Dated: October 31, 2016 Received: November 3, 2016
Dear Ms. Yin:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in
{1}------------------------------------------------
the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Brian D. Pullin -S
for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
## Indications for Use
510(k) Number (if known) K160941
Device Name Castor NC PTA Balloon Dilatation Catheter Achilles NC PTA Balloon Dilatation Catheter Hermes NC PTA Balloon Dilatation Catheter
Indications for Use (Describe)
The balloon dilatation catheter is intended to dilate stenoral, iliofemoral, popliteal, infrapopliteal, and renal arteries, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for stent dilatation post-deployment in the peripheral vasculature.
| Type of Use (Select one or both, as applicable) | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|
| <table><tr><td><span style="font-size: 10pt;"> <span style="font-family: Wingdings;">☑</span> </span> Prescription Use (Part 21 CFR 801 Subpart D) </td></tr></table> | <span style="font-size: 10pt;"> <span style="font-family: Wingdings;">☑</span> </span> Prescription Use (Part 21 CFR 801 Subpart D) |
| <span style="font-size: 10pt;"> <span style="font-family: Wingdings;">☑</span> </span> Prescription Use (Part 21 CFR 801 Subpart D) | |
| <table><tr><td><span style="font-size: 10pt;"> <span style="font-family: Wingdings;">☐</span> </span> Over-The-Counter Use (21 CFR 801 Subpart C) </td></tr></table> | <span style="font-size: 10pt;"> <span style="font-family: Wingdings;">☐</span> </span> Over-The-Counter Use (21 CFR 801 Subpart C) |
| <span style="font-size: 10pt;"> <span style="font-family: Wingdings;">☐</span> </span> Over-The-Counter Use (21 CFR 801 Subpart C) | |
## CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
## *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
## 510(k) Summary
This 510(k) Summary is submitted in accordance with 21 CFR 807.92(c).
| Submitter: | BrosMed Medical Co., Ltd<br>15th Building, SMEs Venture Park<br>SongShan Lake Hi-Tech Industrial Development Zone<br>Dongguan 523808, China<br>Office: +86 (769) 2289 2018<br>Fax: +86 (769) 2289 2016 |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Tina Yin |
| Date Prepared | December 2, 2016 |
| Trade Name: | Castor NC PTA Balloon Dilatation Catheter<br>Achilles NC PTA Balloon Dilatation Catheter<br>Hermes NC PTA Balloon Dilatation Catheter |
| Common Name: | PTA Balloon Dilatation Catheter |
| Classification Name: | Percutaneous catheter (21 CFR 870.1250, Product Code LIT) |
| Predicate Devices: | NanoCross™ Elite 0.014" Over-the-Wire PTA Balloon Dilatation Catheter<br>(K141118; cleared July 18, 2014)<br>Sterling Over-the-Wire (OTW) PTA Balloon Dilatation Catheter<br>(K132430; cleared October 17, 2013)<br>Mustang TM Balloon Dilatation Catheter (K103751; cleared March 22, 2011) |
| Device Description: | The non-compliant PTA (Over-the-Wire, OTW) balloon dilatation catheter<br>family consists of Castor NC (0.014"), Achilles NC (0.018") and Hermes NC<br>(0.035") PTA balloon catheter. The PTA (OTW type) device is an over the<br>wire (OTW) peripheral balloon catheter, specially designed for Percutaneous<br>Transluminal Angioplasty (PTA). The catheter working length is 70, 90 and<br>150cm. Balloon diameters range from Ø2.0mm to Ø10.0mm, balloon work<br>length range from 10mm to 150mm. The three PTA balloon dilatation<br>catheters are filed in one 510(k) submission due to the similar/equivalent<br>construction and identical material of the products. The comparison of them<br>was summarized in Table 1. The differences only exist in the guide wire<br>compatibility and the balloon configuration which have been controlled by the<br>Design Verification. The balloon material is made of a non-compliant Nylon<br>material for diameter 2.0mm to 10.0mm with a rated burst pressure of 18-22<br>atmospheres. It is a coaxial double lumen catheter with a balloon located near<br>the distal tip. One lumen is used for inflation of the balloon and accessed via<br>the side leg port. The second lumen, starting at the straight entry port, allows<br>access to the distal tip of the catheter for guide wire insertion. The three<br>products of the non-compliant PTA (OTW type) balloon catheter family have<br>different diameter of the guide wire port from max.0.014" to 0.035". The<br>guide wire compatibility was shown in table 1. The balloon has radiopaque<br>markers for positioning the balloon relative to the stenosis. The radiopaque<br>marker bands indicate the dilating section of the balloon and aid in balloon<br>placement. The balloon is dilated using the side leg port, at which the balloon<br>material expands to a known diameter at specific pressure. The working<br>pressure range for the balloon is between the nominal size pressure and the<br>rated burst pressure. All balloons distend to sizes above the nominal size at<br>pressures greater than the nominal pressure. The design of this dilatation |
{4}------------------------------------------------
| | | catheter does not incorporate a lumen for distal dye injections or distal | | | | |
|------------------------|--|---------------------------------------------------------------------------|--|--|--|--|
| pressure measurements. | | | | | | |
- Intended Use: The balloon dilatation catheter is intended to dilate stenoses in the iliac, femoral, iliofemoral, popliteal, infrapopliteal, and renal arteries, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for stent dilatation post-deployment in the peripheral vasculature.
- Comparisons of the new and predicate devices show that the technological Technological Characteristics: characteristics such as product performance, design, and intended use are substantially equivalent to the currently marketed predicate devices.
- Performance Data: Both in vitro performance tests, such as dimensional verification, balloon preparation, deployment, and retraction, balloon rated burst pressure, balloon fatigue, balloon compliance, balloon inflation and deflation time, catheter bond strength, tip pull strength, flexibility and kinking, torque strength, radiopacity, coating integrity, particulate evaluation, balloon burst (in stents), balloon fatigue (in stents) and also biocompatibility tests, such as cytotoxicity, sensitization, hemocompatibility, pyrogenicity, acute systemic toxicity, intracutaneous reactivity and genototocity (bacterial mutagenicity and in vitro mouse lymphoma) were conducted on the PTA balloon catheter. The test results met all acceptance criteria, were similar to predicate devices, and ensure that the PTA balloon catheter design and construction are suitable for its intended use.
- Conclusion: This information supports a determination of substantial equivalence between the PTA balloon dilatation catheter and the predicate devices described above.
{5}------------------------------------------------
| | Castor NC 0.014 | Achilles NC 0.018 | Hermes NC 0.035 | Difference | Control<br>Method |
|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------------------------------|
| Device | catheter, angioplasty,<br>peripheral, transluminal | catheter, angioplasty,<br>peripheral, transluminal | catheter, angioplasty,<br>peripheral, transluminal | Identical | |
| Regulation<br>Description | Percutaneous catheter. | Percutaneous catheter. | Percutaneous catheter. | Identical | |
| Regulation Medical<br>Specialty | Cardiovascular | Cardiovascular | Cardiovascular | Identical | |
| Review Panel | Cardiovascular | Cardiovascular | Cardiovascular | Identical | |
| Product Code | LIT | LIT | LIT | Identical | |
| | Office of Device Evaluation<br>6(ODE) | Office of Device Evaluation<br>6(ODE) | Office of Device Evaluation<br>6(ODE) | Identical | n/a |
| Premarket Review | Division of Cardiovascular<br>Devices (DCD) | Division of Cardiovascular<br>Devices (DCD) | Division of Cardiovascular<br>Devices (DCD) | Identical | |
| | Peripheral Interventional<br>Devices Branch (PIDB) | Peripheral Interventional<br>Devices Branch (PIDB) | Peripheral Interventional<br>Devices Branch (PIDB) | Identical | |
| Submission Type | 510(k) | 510(k) | 510(k) | Identical | |
| Regulation Number | 21 CFR 870.1250 | 21 CFR 870.1250 | 21 CFR 870.1250 | Identical | |
| Device Class | 2 | 2 | 2 | Identical | |
| Indications for Use | The PTA balloon dilatation<br>catheter is indicated for:<br>• dilating stenoses in the<br>iliac, femoral, iliofemoral,<br>popliteal, infrapopliteal, and<br>renal arteries, and for the<br>treatment of obstructive<br>lesions of native or synthetic<br>arteriovenous dialysis<br>fistulae.<br>• stent dilatation<br>post-deployment in the<br>peripheral vasculature. | The PTA balloon dilatation<br>catheter is indicated for:<br>• dilating stenoses in the<br>iliac, femoral, iliofemoral,<br>popliteal, infrapopliteal, and<br>renal arteries, and for the<br>treatment of obstructive<br>lesions of native or synthetic<br>arteriovenous dialysis<br>fistulae.<br>• stent dilatation<br>post-deployment in the<br>peripheral vasculature. | The PTA balloon dilatation<br>catheter is indicated for:<br>• dilating stenoses in the<br>iliac, femoral, iliofemoral,<br>popliteal, infrapopliteal, and<br>renal arteries, and for the<br>treatment of obstructive<br>lesions of native or synthetic<br>arteriovenous dialysis<br>fistulae.<br>• stent dilatation<br>post-deployment in the<br>peripheral vasculature. | Identical | IFU |
| Balloon<br>Characteristic | non-compliant | non-compliant | non-compliant | Identical | Design<br>Verification;<br>labeling |
| Nominal<br>Pressure (Nom) | 12atm | 12atm | 12atm | Identical | Design<br>Verification;<br>labeling |
| Rated Burst<br>Pressure (RBP) | 18, 20, 22atm | 18, 20, 22atm | 18, 20, 22atm | Identical | Design<br>Verification;<br>labeling |
| Guide wire<br>Compatibility | Max. 0.014"(0.36mm) | Max. 0.018" (0.46mm) | Max. 0.035"(0.89mm) | Different | Design<br>Verification;<br>labeling |
| Balloon<br>Diameter | 2.0-8.0mm | 2.0-8.0mm | 3.0-10.0mm | Different | Design<br>Verification:<br>labeling |
| Balloon Length | 10-150mm | 10-150mm | 20-150mm | Different | Design<br>Verification:<br>labeling |
| Shaft Length | 70, 90, 150 | 70, 90, 150 | 70, 90, 150 | Identical | Design<br>Verification:<br>labeling |
Table 1, BrosMed PTA Balloon Dilatation Catheter Comparison Table
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.
Copy this now. It will not be shown again.
Connected apps
Apps you authorized through browser sign-in. Disconnecting revokes their access immediately.
Learn the FDA Browser
Two short videos show you everything — or skip straight to the written tutorial if you'd rather read. You can reopen this any time from the Tutorial button in the top bar.
Part 1 — Search, results, and everyday workflows 16 min
Part 2 — Embeddings: the galaxy map 3 min
1. Search: exact and fuzzy
Type a phrase like "coronary artery calcification" into the search box. You get two kinds of results. Exact results match the literal phrase — prefix searches work ("coronary artery calcificati") but suffix searches do not. Fuzzy results match on the meaning and intent of your phrase rather than the exact words, and are sorted by relevance score. Hover over the Exact or Fuzzy badge on any row to see exactly why it matched.
Use the checkboxes above the results to narrow: SaMD keeps only software-only devices, AI / ML keeps only devices with AI.
Exact vs. fuzzy search: what's the difference?
Exact matches on the literal phrase (prefix search works, suffix does not). Fuzzy matches on the meaning and intent of the phrase rather than the exact words. Hover over the badge on any row to see why it matched.
You search "coronary artery calcification" and want only software devices with AI. What two filters do you apply?
Narrow by SaMD (software-only devices), then narrow by AI/ML (devices with AI).
2. The results table
Scroll right in the results table. The intended use is extracted for you — no need to open the PDF. The device story gives a high-level snapshot of what the device does and how it's used. The AI Performance sub-table shows each output name, acceptance criteria, observed values, and development/test dataset descriptions — the same format Innolitics uses for regulatory strategy outputs, and the fastest high-level fingerprint of an AI device. It is AI-generated but has been very reliable in practice.
Where do you find a device's intended use without opening the PDF?
Scroll right in the search results table. The intended use column is extracted for you; no need to dig into the 510(k) summary PDF.
What does the AI Performance sub-table show, and why is it useful?
Output name, acceptance criteria, observed values, development dataset description, and test dataset description. It's the same format we use for regulatory strategy output and Fast 510(k) input, and the fastest high-level fingerprint of an AI device. AI-generated but reliable in practice.
3. Judging fuzzy relevance
Fuzzy results trail off in relevance as you scroll. Use three signals to decide how far down to go: the fuzzy badge explanations, the intended use column, and whether your target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, you're past the relevant zone. A top hit with a low score (~0.4) and a stretched explanation is a hint the closest predicates are far away — the project may be headed for De Novo. Note the fuzzy search is a pattern match: it doesn't handle negation ("not") well, and hardware devices can appear — filter by SaMD/AI ML to cut them.
How do you judge how far down fuzzy search results to go?
Use the relevancy signals: the fuzzy badge explanations, the intended use column, and whether the target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, results are trailing off in relevancy.
4. Device detail page: chat and citations
Click a device name to open its detail page: device facts on the left, a chat window on the right. Ask something like "Describe the training data". The answer carries little citation bubbles — click one to jump to the highlighted passage in the source PDF, so you can verify every AI answer against the document. There's also a Download PDF button for sharing.
How do you verify an AI chat answer on the device detail page?
Click the citation bubbles to jump to the relevant highlight in the source document.
Reading rule for every project: how many summaries do you read in full?
At least the three most relevant 510(k) or De Novo summaries, in full. After that, use targeted chat questions to confirm your memory quickly. The tool supports this professional habit — it doesn't replace it.
5. Side-by-side comparison
Select multiple rows in the results table (aim for under ~10), then open the PDF Viewer tab. Ask one question — it goes to all selected devices in parallel, each with citations. This is the fastest way to compare and contrast devices: training data, PCCP scope, how they handled adding new scanners, and so on.
What does the side-by-side PDF viewer mode do?
Select multiple devices, open the PDF viewer tab, and ask one question (e.g., "Describe the training data"). It queries all selected devices simultaneously with citations, so you can compare and contrast quickly.
6. Collections
With rows selected, go to the Collections tab and create a labeled collection (e.g., "Cobb Angle Project"). Reload that selection any time — before a client call, pull up the collection and ask questions across all of its devices at once.
How do you save a set of selected devices for later use?
Select the rows, go to the Collections tab, and create a labeled collection (e.g., "Cobb Angle Project"). You can reload the selection anytime and carry it into the PDF viewer and other tabs that support selections.
7. Product codes and the regulations tree
Click a product code in the results to jump to it in the regulations tree — identification text, sibling product codes, and devices you can open in a PDF viewer on the right. Click a regulation number to see its identification, special controls, and related product codes. You can also search by product code or regulation number at the top of the tree. Always read the special controls if any exist for your device — it broadens your search and sharpens pre-kickoff research.
What can you do from the regulations tree view?
Browse product codes and regulation numbers, read the identification text and special controls, browse sibling product codes, open device PDFs on the right, and search by product code or regulation number at the top of the tree.
8. Chart view
Click Show Chart and segment by regulation number (or product code) to see which regulations dominate your result set. Clicking a regulation takes you into the regulations tree. Great for spotting that most matches are, say, hardware laparoscopic devices — a cue to go back and filter.
How do you see which regulations dominate a search result set?
Click "Show Chart" and segment by Regulation Number. Clicking a regulation takes you to the regulations tree.
9. The predicate graph
Open the Predicates tab for a family-tree view of predicate relationships. Click a node to trace its parents and children; selections from search carry over pre-selected. Commonly predicated devices are worth reading — a lot of people predicated them for a reason. The visual lineage is also handy on client calls, e.g. to show how a predicate family evolved and justify why your predicate still holds.
In the predicate graph, why are commonly predicated devices worth reading?
A lot of people predicated them for a reason. Clicking a node traces parents and children, and selections from search carry over pre-selected.
10. Embeddings: the galaxy map
The Embeddings tab plots every matching document in a 2-D "galaxy map" where semantically similar devices cluster together. Hover or click clusters to explore, and let AI label the clusters for you. Embeddings beat product codes for grouping: two devices can carry different product codes (LLZ vs. QIH) yet do the same thing — the embedding captures the meaning of the intended use and device story. This is also exactly how retrieval-augmented generation (RAG) works under the hood, and it makes a great visual on client calls.
Try it yourself
Head to the search page and work through a few of these AI/ML fuzzy searches to build intuition: perivascular fat on CT · aortic valve calcification opportunistic screening on noncontrast CT · breast cancer prediction on digital pathology slides · autism detection · gestational age prediction · a hearing aid that can also detect a pulse · foundation model based analysis of ECG · large language models · penetration test. Watch how the relevance scores, intended use, and AI Performance tables tell you when results stop being meaningful.